Non-motor symptoms in Parkinson's disease: an underdiagnosed problem

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Parkinson J: An essay on the shaking palsy [reprint of monograph published by Sherwood, Neely, and Jones, London, 1817]. J. Neuropsychiatry Clin. Neurosci.14,223–236 (2002).
  MedlineGoogle Scholar
• 2  Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry55(3),181–184 (1992).•• Classic paper attempting refinement of clinical diagnosis of Parkinson's disease (PD) using postmortem validation of clinical diagnosis.
  Medline CASGoogle Scholar
• 3  Movement Disorder Society Task Force on Rating Scales for Parkinson's disease: The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov. Disord.18(7),738–750 (2003).• Useful paper highlighting the need for the unified PD rating scale (UPDRS) to be amended with incorporation of non-motor items.
  MedlineGoogle Scholar
• 4  Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology56(Suppl. 5),S1–S88 (2001).
  Medline CASGoogle Scholar
• 5  Global Parkinson's disease Survey Steering Committee: Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov. Disord.17(1),60–67 (2002).•• A large, real-life study highlighting the role of non-motor symptoms (NMS) and their impact on quality of life in people with PD.
  MedlineGoogle Scholar
• 6  Chaudhuri KR, Schapira AHV, Martinez-Martin P et al.: The holistic management of Parkinson's using a novel non-motor symptom scale and questionnaire. Adv. Clin. Neurosci. Rehab.4,20–24 (2004).
  Google Scholar
• 7  Aarsland D, Larsen JP, Tandberg E, Laake K: Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J. Am. Geriatr. Soc.48(8),938–942 (2000).• Important study showing the impact of NMS in PD and institutionalization.
  Medline CASGoogle Scholar
• 8  Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson's disease? J. Neurol. Neurosurg. Psychiatry69(3),308–312 (2000).• Important study showing the role of depression and its impact on quality of life in PD.
  Medline CASGoogle Scholar
• 9  Findley L, Aujla M, Bain PG et al.: Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov. Disord.18(10),1139–1145 (2003).•• Important study providing an evidence base for the increasing cost of care with advancing PD associated with NMS.
  MedlineGoogle Scholar
• 10  Hagell P, Nordling S, Reimer J, Grabowski M, Persson U: Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov. Disord.17(6),1213–1220 (2002).
  MedlineGoogle Scholar
• 11  Pressley JC, Louis ED, Tang MX et al.: The impact of comorbid disease and injuries on resource use and expenditures in Parkinsonism. Neurology60(1),87–93 (2003).
  Medline CASGoogle Scholar
• 12  Chaudhuri KR, Yates L, Martinez-Martin P: The non-motor symptom complex of Parkinson's disease: time for a comprehensive assessment. Curr. Neurol. Neurosci. Rep.5,275–283 (2005).
  MedlineGoogle Scholar
• 13  Hely MA, Morris JGL, Reid WGJ, Trafficante R: Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord.20,190–199 (2005).•• Classic and important study following up patients recruited to the Sydney bromocriptine vs levodopa study and showing that at 15 years NMS dominate the clinical picture and influence morbidity.
  MedlineGoogle Scholar
• 14  Shulman LM, Taback RL, Rabinstein AA, Weiner WJ: Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord.8(3),193–197 (2002).•• First paper to identify the failure of neurologists to clinically recognize and tackle NMS in real life clinical practice.
  Medline CASGoogle Scholar
• 15  Chaudhuri KR, Healy DG, Schapira AH: Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol.5(3),235–245 (2006).•• Comprehensive review of NMS in PD. Clinical impact, premotor features and management.
  MedlineGoogle Scholar
• 16  Chaudhuri KR, Martinez-Martin P, Schapira AHV et al.: An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov. Disord.21(7),916–923 (2006).•• First study to internationally validate a self-completed questionnaire (NMSQuest) comprehensively flagging the NMS of PD in the clinic.
  MedlineGoogle Scholar
• 17  Zgaljardic DJ, Foldi NS, Borod JC: Cognitive and behavioural dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J. Neural Transm.111,1287–1301 (2004).
  Medline CASGoogle Scholar
• 18  Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging24,197–210 (2003).•• Groundbreaking paper suggesting that the pathology of PD starts in the brainstem and the olfactory bundles rather than the substantia nigra based on Lewy body pathology.
  MedlineGoogle Scholar
• 19  Del Tredici K, Braak H: Idiopathic Parkinson's disease: staging an α-synucleinopathy with a predictable pathoanatomy. In: Molecular mechanisms in Parkinson's disease. Kahle P, Haass C (Eds). Landes Bioscience, Georgetown, TX USA, 1–32 (2004).
  Google Scholar
• 20  Berg D: In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage. J. Neural Transm.113(3),775–780 (2006).• Important paper suggesting that transcranial ultrasound examination may detect PD.
  Medline CASGoogle Scholar
• 21  Berendse HW: Early diagnosis in PD: olfaction. Parkinsonism Relat. Disord.12(1),1–2 (2006).
  Google Scholar
• 22  Montgomery EB Jr, Baker KB, Lyons K et al.: Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology52,757–762 (1999).
  MedlineGoogle Scholar
• 23  Muller A, Abolmaali ND, Hakimi AR et al.: Olfactory bulb volumes in patients with idiopathic Parkinson's disease-a pilot study. J. Neural Transm.112,1363–1370 (2005).
  MedlineGoogle Scholar
• 24  Boeve BF, Silber MH, Ferman TJ et al.: Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord.16,622–630 (2001).
  Medline CASGoogle Scholar
• 25  Hawkes C: Olfaction in neurodegenerative disorders. Mov. Disord.18,364–372 (2003).• Important paper suggesting that olfactory problems are common in PD and need recognition, and may precede the diagnosis of PD.
  MedlineGoogle Scholar
• 26  Ponsen MM, Stoffers D, Booij J, Van Eck-Smit BL, Wolters EC, Berendse HW: Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol.56(2),173–181 (2004).• Olfactory deficits are common in PD and may precede the diagnosis of PD.
  MedlineGoogle Scholar
• 27  Sommer U, Hummel T, Cormann K et al.: Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov. Disord.19(10),1196–1202 (2004).•• Important paper suggesting a premotor diagnostic package for PD.
  MedlineGoogle Scholar
• 28  Comella CL, Tanner CM, Ristanovic RK: Polysomnographic sleep measures in Parkinson's disease patients with treatment induced hallucinations. Ann. Neurol.34,710–714 (1993).
  Medline CASGoogle Scholar
• 29  Ohayon MM, Caulet M, Priest RG: Violent behaviour during sleep. J. Clin. Psychiatry58,369–376 (1997).
  Medline CASGoogle Scholar
• 30  Rye DB: The two faces of eve. Dopamine's modulation of wakefulness and sleep. Neurology63(3),S2–S7 (2004).•• Classic paper exploring the role of dopamine in sleep–wake cycle homeostasis.
  MedlineGoogle Scholar
• 31  Schenck CH, Bundlie SR, Mahowald MW: Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology46,388–393 (1996).• Two important and pivotal papers addressing the diagnosis and characteristics of rapid eye movement behavior disorder in PD and its role as a premotor symptom.
  Medline CASGoogle Scholar
• 32  Olson EJ, Boeve BF, Silber MH: Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain123,331–339 (2000).•• Two important and pivotal papers addressing the diagnosis and characteristics of rapid eye movement behavior disorder in PD and its role as a premotor symptom.
  MedlineGoogle Scholar
• 33  Gagnon JF, Bedard MA, Fantini ML et al.: REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology59,585–589 (2002).
  Medline CASGoogle Scholar
• 34  Iranzo A, Molinuevo JL, Santamaria J et al.: Rapid eye movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol.5 (7),572–577 (2006).
  MedlineGoogle Scholar
• 35  Stiasny-Kolster K, Doerr Y, Moller JC et al.: Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain128(Pt 1),126–137 (2005).
  Medline CASGoogle Scholar
• 36  Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J: Potential early markers of Parkinson's disease in idiopathic REM sleep behaviour disorder. Neurology66(6),796–797 (2006).
  MedlineGoogle Scholar
• 37  Thanvi BR, Munshi SK, Vijaykumar N, Lo TC: Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad. Med. J.79(936),561–565 (2003).
  Medline CASGoogle Scholar
• 38  Aarsland D, Larsen JP, Goek Lim N et al.: Range of neuropsychiatric disturbances in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry67,492–496 (1999).
  Medline CASGoogle Scholar
• 39  Lauterbach EC: The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr. Clin. North Am.27(4),801–825 (2004).
  MedlineGoogle Scholar
• 40  Burn DJ: Beyond the iron mask; towards better recognition and treatment of depression associated with Parkinson's disease. Mov. Disord.17,445–454 (2002).
  MedlineGoogle Scholar
• 41  Remy P, Doder M, Lees A, Turjanski N, Brooks D: Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain128(Pt 6),1314–1322 (2005).
  MedlineGoogle Scholar
• 42  O'Suilleabhain PE, Sung V, Hernandez C et al.: Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch. Neurol.61,865–868 (2004).
  MedlineGoogle Scholar
• 43  Lauterbach EC, Freeman A, Vogel RL: Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson's disease. J. Neuropsychiatry Clin. Neurosci.16,29–36 (2004).
  MedlineGoogle Scholar
• 44  Nilsson FM, Kessig LV, Bolwig TG: Increased risk of developing Parkinson's disease for patients with major affective disorders. Acta Psychiatr. Scand.104,380–386 (2001).
  Medline CASGoogle Scholar
• 45  Schurmann AG, Van den Akker H, Ensinck KT et al.: Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology58,1501–1504 (2002).
  MedlineGoogle Scholar
• 46  Montgomery EB, Lyons K, Koller WC: Early detection of probable idiopathic Parkinson's disease: II. A prospective application of diagnostic test battery. Mov. Disord.15,474–478 (2000).
  MedlineGoogle Scholar
• 47  Ahlskog JE: Challenging conventional wisdom, the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov. Disord.20(3),271–282 (2005).
  MedlineGoogle Scholar
• 48  Byrne KG, Pfeiffer R, Quigley EM: Gastrointestinal dysfunction in Parkinson's disease. A report of clinical experience at a single center. J. Clin. Gastroenterol.19,11–16 (1994).
  Medline CASGoogle Scholar
• 49  Korczyn AD: Autonomic nervous system screening in patients with early Parkinson's disease. In: Early diagnosis and preventive therapy in Parkinson's disease. Przuntek H, Riederer P (Eds). Springer-Velag, Vienna, 41–48 (1989).
  Google Scholar
• 50  Abbott RD, Petrovitch H, White LR et al.: Frequency of bowel movements and the future risk of Parkinson's disease. Neurology57,456–462 (2001).• Important paper addressing the role of constipation as a premotor feature of PD.
  Medline CASGoogle Scholar
• 51  Edwards LL, Pfeiffer RF, Quigley MM, Hoffman R, Balluf M: Gastrointestinal symptoms in Parkinson's disease. Mov. Disord.6,151–156 (2004).
  Google Scholar
• 52  Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. Neurol. Sci.20,415–455 (1973).
  CASGoogle Scholar
• 53  Aarsland D, Larsen JP, Goek Lim N et al.: Range of neuropsychiatric disturbances in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry67,492–496 (1999).
  Medline CASGoogle Scholar
• 54  Lauterbach EC: The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr. Clin. North Am.27(4),801–825 (2004).
  MedlineGoogle Scholar
• 55  Shiba M, Bower JH, Maraganore DM et al.: Anxiety disorders and depressive disorders preceding Parkinson's disease: a case–control study. Mov. Disord.15,669–677 (2000).
  Medline CASGoogle Scholar
• 56  Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A: Prospective study of phobic anxiety and risk of Parkinson's disease. Mov. Disord.18(6),646–651 (2003).
  MedlineGoogle Scholar
• 57  Aarsland D, Ehrt U: The epidemiology of mental dysfunction in Parkinson's disease. In: Mental Dysfunction in Parkinson's disease III. Wolters E, Berendse HW, Stam CJ (Eds). VU University Press, Amsterdam, Holland, 95–108 (2006).
  Google Scholar
• 58  Richard IH: Anxiety disorders in Parkinson's disease. Adv. Neurol.96,42–55 (2005).
  MedlineGoogle Scholar
• 59  Singh A, Althoff R, Martineau J, Jacobson J: Pramipexole, Ropinirole, and Mania in Parkinson's disease. Am. J. Psychiatry162,814–815 (2005).
  MedlineGoogle Scholar
• 60  Starkstein SE, Mayberg SE, Preziosi TJ et al.: Reliability, validity and clinical correlates of apathy in Parkinson's disease. J. Neuropsychiatry4,134–139 (1992).
  Medline CASGoogle Scholar
• 61  Pluck GC, Brown RG: Apathy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry73,636–642 (2002).
  Medline CASGoogle Scholar
• 62  Alves G, Wentzel-Larsen T, Larsen JP: Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology10,1908–1911 (2004).
  Google Scholar
• 63  Brown RG, Pluck G: Negative symptoms: the ‘pathology’ of motivation and goal-directed behaviour. Trends Neurosci.23(9),412–417 (2000).• Paper outlining the identification and pathophysiology of motivation and reward-seeking behavior.
  Medline CASGoogle Scholar
• 64  Diederich NJ, Goetz CG, Stebbins GT: Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov. Disord.20,130–140 (2005).•• Important paper addressing the pathophysiology of hallucinations in PD.
  MedlineGoogle Scholar
• 65  Fenelon G, Mahieux F, Huon R et al.: Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain123,733–745 (2000).
  MedlineGoogle Scholar
• 66  Kipps CM, Fung VSC, Grattan-Smith P, de Moore GM, Morris JGL: Movement disorder emergencies. Mov. Disord.20,322–334 (2005).
  MedlineGoogle Scholar
• 67  Onofrj M, Thomas A, D'Andreamatteo G et al.: Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol. Sci.23,S91–S94 (2002).
  MedlineGoogle Scholar
• 68  Moskovitz C, Moses H, Klawans HL: Levodopa-induced psychosis: a kindling phenomenon. Am. J. Psychiatry.135,669–675 (1978).
  Medline CASGoogle Scholar
• 69  Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L: Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch. Neurol.61(8),1280–1284 (2004).
  MedlineGoogle Scholar
• 70  Reuter J, Raedler T, Rose M et al.: Pathological gambling is linked to reduced activation in the mesolimbic reward system. Nature Neurosci.8(2),147–148 (2005).
  Medline CASGoogle Scholar
• 71  Pezzella FR, Colosimo C, Vanacore N et al.: Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov. Disord.20(1),77–81 (2005).
  MedlineGoogle Scholar
• 72  Emre M: Dementia associated with Parkinson's disease. Lancet Neurol.2(4),229–237 (2003).• A comprehensive review of dementia in PD.
  Medline CASGoogle Scholar
• 73  Aarsland D, Andersen K, Larsen JP et al.: The rate of cognitive decline in Parkinson disease. Arch. Neurol.61(12),1906–1911 (2004).•• Important paper outlining the rate of decline of cognition in PD.
  MedlineGoogle Scholar
• 74  Apaydin H, Ahlskog E, Parisi JE, Boeve BF, Dickson DW: Parkinson disease neuropathology: late-developing dementia and loss of the levodopa response. Arch. Neurol.59,102–112 (2002).
  MedlineGoogle Scholar
• 75  Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M: α-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol.100,285–290 (2000).
  Medline CASGoogle Scholar
• 76  Hurtig HI, Trojanowski JQ, Galvin J et al.: α-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology54,1916–1921 (2000).
  Medline CASGoogle Scholar
• 77  Laakso MP, Partanen K, Riekkinen P et al.: Hippocampal volumes in Alzheimer's disease, Parkinson's disease with or without dementia: an MRI study. Neurology46,678–681 (1996).
  Medline CASGoogle Scholar
• 78  Chaudhuri KR: Nocturnal symptom complex in PD and its management. Neurology61(3),S17–S23 (2003).
  Medline CASGoogle Scholar
• 79  Lees AJ, Blackburn NA, Campbell VL: The nighttime problems of Parkinson's disease. Clin. Neuropharmacol.11,512–519 (1988).
  Medline CASGoogle Scholar
• 80  Garcia-Borreguero D, Larosa O, Bravo M: Parkinson's disease and sleep. Sleep Med. Rev.7,115–129 (2003).
  MedlineGoogle Scholar
• 81  Rye DB, Jankovic J: Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology58,341–346 (2002).
  MedlineGoogle Scholar
• 82  Lai YY, Siegel JM: Muscle tone suppression and stepping produced by stimulation of midbrain and rostral pontine reticular formation. J. Neurosci.10(8),2727–2734 (1990).
  Medline CASGoogle Scholar
• 83  Shouse MN, Siegel JM: Pontine regulation of REM sleep components in cats: integrity of the pedunculopontine tegmentum (PPT) is important for phasic events but unnecessary for atonia during REM sleep. Brain Res.571,50–63 (1992).
  Medline CASGoogle Scholar
• 84  Dhawan V, Healy DG, Pal S, Chaudhuri KR: Sleep-related problems of Parkinson's disease. Age Ageing35,220–228 (2006).• Important up-to-date review of sleep problems in PD and how these can be managed.
  Medline CASGoogle Scholar
• 85  Arnulf I, Konofal E, Merino-Andreu M et al.: Parkinson's disease and sleepiness – an integral part of PD. Neurology58,1019–1024 (2002).•• Classic paper outlining the importance of addressing sleepiness in PD and how a proportion may even show a narcoleptic phenotype.
  Medline CASGoogle Scholar
• 86  Abbott RD, Ross GW, White LR et al.: Excessive daytime sleepiness and the future risk of Parkinson's disease. Mov. Disord.20(Suppl. 10),S101 (P341) (2005).
  Google Scholar
• 87  MacMahon D: Why excessive daytime sleepiness is an important issue in Parkinson's disease. Adv. Clin. Neurol. Rehab.5(2),46–49 (2005).
  Google Scholar
• 88  Saper C, Chou TC, Scammell TE: The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci.24,726–731 (2001).•• Seminal paper outlining the ‘flip–flop’ switch of wakefulness and sleep.
  Medline CASGoogle Scholar
• 89  Crocker A, Espana A, Papadopoulou BS et al.: Concommitant loss of dynorphin, NARP and orexin in narcolepsy. Neurology65(8),1184–1188 (2005).
  Medline CASGoogle Scholar
• 90  Chaudhuri KR: Autonomic dysfunction in movement disorders. Curr. Opin. Neurol.14,505–511 (2001).
  Medline CASGoogle Scholar
• 91  Benarroch EE: Central neurotransmitters and neuromodulators in cardiovascular regulation. In: Autonomic failure, 4th Edition. Mathias CJ, Bannister R (Eds). Oxford University Press, Oxford, UK, 37–44 (1999).
  Google Scholar
• 92  Magerkurth C, Schnitzer R, Braune S: Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin. Auton. Res.15,76–82 (2005).
  MedlineGoogle Scholar
• 93  Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannonn RO 3rd: Cardiac sympathetic denervation in Parkinson's disease. Ann. Int. Med.133(5),338–347 (2000).• Elegant demonstration of the importance of sympathetic dysfunction in PD and how cardiac imaging may help with diagnosis.
  Medline CASGoogle Scholar
• 94  Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH: Cardiac uptake of [123I] MIBG separates Parkinson's disease from multiple systems atrophy. Neurology53,1020–1025 (1999).•• Elegant demonstration of the importance of sympathetic dysfunction in PD and how cardiac imaging may help with diagnosis.
  Medline CASGoogle Scholar
• 95  Winge K, Fowler CJ: Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov. Disord.21(6),737–745 (2006).
  MedlineGoogle Scholar
• 96  Herlofson K, Larsen JP: The influence of fatigue on health related quality of life in patients with Parkinson's disease. Acta Neurol. Scand.107(1),1–6 (2003).
  Medline CASGoogle Scholar
• 97  Karlsen K, Larsen JP, Tandberg E, Jorgensen K: Fatigue in patients with Parkinson's disease. Mov. Disord.14,237–241 (1999).
  Medline CASGoogle Scholar
• 98  Alves G, Wentzel-Larsen T, Larsen JP: Is fatigue an independent and persistent symptom in patients with Parkinson's disease? Neurology63,1908–1911 (2004).
  Medline CASGoogle Scholar
• 99  Brown RG, Jahanshahi M, Quinn N, Marsden CD: Sexual function in patients with Parkinson's disease and their partners. J. Neurol. Neurosurg. Psychiatry53,480–486 (1990).
  Medline CASGoogle Scholar
• 100  Okun M, Walter BL, McDonald WM et al.: Beneficial effects of testosterone replacement for the non motor symptoms of Parkinson's disease. Arch. Neurol.59(11),1750–1753 (2002).
  MedlineGoogle Scholar
• 101  Tyvaert L, Devos D, Rigot JM, Blond S, Reyns N, Destee A: Sexual dysfunction and sub-thalamic stimulation in Parkinson's disease. Parkinsonism Relat. Disord.11(2),116 (2005).
  Google Scholar
• 102  Scherder E: Pain in Parkinson's disease. Parkinson's disease-related cognitive dysfunction. Parkinsonism Relat. Disord.12(1),2 (2006).
  Google Scholar
• 103  Waseem S, Gwinn-Hardy K: Pain in Parkinson's disease. Common yet seldom-recognized symptom is treatable. Postgrad. Med.110(6),33–40 (2001).
  Medline CASGoogle Scholar
• 104  Goetz CG, Tanner CM, Levy M et al.: Pain in Parkinson's disease. Mov. Disord.1(1),45–49 (1986).•• A classic paper describing the role of pain in PD recognition and management.
  Medline CASGoogle Scholar
• 105  Quinn NP, Koller WC, Lang AE et al.: Painful Parkinson's disease. Lancet1(8494),1366–1369 (1996).•• A classic paper describing the role of pain in PD recognition and management.
  Google Scholar
• 106  Ford B, Louise P, Greene P et al.: Oral and genital pain syndromes in Parkinson's disease. Mov. Disord.11(4),421–426 (1996).
  Medline CASGoogle Scholar
• 107  Hillen ME, Sage JI: Nonmotor fluctuations in patients with Parkinson disease. Neurology47(5),1180–1183 (1996).
  Medline CASGoogle Scholar
• 108  Stacy M, Bowron A, Guttman M, Hauser R: Identification of motor and nonmotor wearing – off in Parkinson's disease: a comparison of patient questionnaire versus a clinician assessment. Mov. Disord.20(6),726–733 (2005).
  MedlineGoogle Scholar
• 109  Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety11(2),58–65 (2000).
  Medline CASGoogle Scholar
• 110  Byrne R, Chaudhuri KR: Depression a key nonmotor symptom of Parkinson's disease. Prog. Neurol. Psychiatry10(5),15–21 (2006).
  Google Scholar
• 111  Rektorova I, Rektor I, Bares M et al.: Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur. J. Neurol.10(4),399–406 (2003).
  Medline CASGoogle Scholar
• 112  Singh A, Althoff R, Martineau RJ, Jacobson J: Pramipexole, ropinorole and mania in Parkinson's disease. Am. J. Psychiatry162(4),814–815 (2005).
  MedlineGoogle Scholar
• 113  Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K, Parkinson Study group: Clozapine for treatment of drug-induced psychosis in Parkinson's disease: results of the 12-week open label extension in the PSYCLOPS trial. Mov. Disord.16,135–139 (2001).
  Medline CASGoogle Scholar
• 114  Ondo WG, Tintner R, Vuong Dat K, Lai D, Ringholz G: Double blind placebo controlled unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord.20,958–963 (2005).
  MedlineGoogle Scholar
• 115  Seemau P: Atypical antipsychotics mechanism of action. Can. J. Psychiatry47,27–38 (2002).
  MedlineGoogle Scholar
• 116  Factor SA, Brown D: Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov. Disord.7(2),125–1231 (1992).
  Medline CASGoogle Scholar
• 117  Emre M, Aarsland D, Albanese A et al.: Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med.351,2509–2518 (2004).
  Medline CASGoogle Scholar
• 118  Ravina B, Putt M, Siderowf A, Farrar JT et al.: Donezepil for dementia in Parkinson's disease: a randomised double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76(7),934–939 (2005).
  Medline CASGoogle Scholar
• 119  Adler CH, Caviness JN, Hentz JG et al.: Randomised trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov. Disord.18,287–293 (2003).
  MedlineGoogle Scholar
• 120  Hogl B, Saletu B, Brandauer E et al.: Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double blind, randomised, crossover, placebo controlled, polygraphic trial. Sleep25(8),905–909 (2002).• Study addressing the role of modafinil in PD.
  Medline CASGoogle Scholar
• 121  Ondo WG, Fayle R, Atassi F, Jankovic J: Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J. Neurol. Neurosurg. Psychiatry76(12),1636–1639 (2005).•• Study addressing the role of modafinil in PD and reporting contradictory results.
  Medline CASGoogle Scholar
• 122  Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG: Botulinum toxin type A for drooling in Parkinson's disease: a double blind, randomized, placebo-controlled study. Mov. Disord.21,704–707 (2006).
  MedlineGoogle Scholar
• 123  Raffaele R, Vecchio I, Giammuso B et al.: Efficacy and safety of fixed dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur. Urol.41(4),382–386 (2002).
  Medline CASGoogle Scholar
• 124  Eichhorn TE, Oertel WH: Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov. Disord.16,1176–1177 (2001).
  Medline CASGoogle Scholar
• 125  Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI: Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta analysis. Lancet Neurol.5,578–588 (2006).
  MedlineGoogle Scholar
• 126  Kalteis K, Standhartdt H, Kryspin-Exner I, Brucke T, Volt D, Ales F: Influence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson's disease. J. Neural Transm.113(9),1191–1206 (2005).
  MedlineGoogle Scholar
• 127  Castelli L, Perozzo P, Zibetti M et al.: Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits. Eur. Neurol.55(3),136–144 (2006).
  Medline CASGoogle Scholar
• 128  Wermuth L, Sorensen PS, Timm S et al.: Depression in idiopathic Parkinson's disease treated with citalopram; a placebo controlled trial. Nord. J. Psychiatry52,163–169 (1998).
  Google Scholar
• 129  Leentjens AF, Vreeling FW, Luijckx GJ et al.: SSRIs in the treatment of depression in Parkinson's disease. Int. J. Geriatr. Psychiatry18,552–554 (2003).
  Medline CASGoogle Scholar
• 130  Barone P, Scarzella L, Marconi R et al.: Pramipexole versus sertaline in the treatment of depression in Parkinson disease: a national multicentre parallel-group randomized study. J. Neurol.253(5),601–607 (2006).
  Medline CASGoogle Scholar
• 131  Fregni F, Santos CM, Myczkowski ML et al.: Repetitive transcranial magnetic stimulation is as effective as fluoxetine inn the treatment of depression in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry75(8),1171–1174 (2004).
  Medline CASGoogle Scholar
• 132  Ondo WG, Tintner R, Vuong Dat K, Lai D, Ringholz G: Double blind placebo controlled unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord.20,958–963 (2005).•• Important double-blind trial of a neuroleptic commonly used in clinical practice in PD.
  MedlineGoogle Scholar
• 133  The Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med.340,757–763 (1999).
  MedlineGoogle Scholar
• 134  Goetz CG, Blasucci LM, Leyrgans S, Pappert EJ: Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology55,789–794 (2000).
  Medline CASGoogle Scholar
• 135  Hjort N, Ostergaard K, Dupont E: Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Mov. Disord.19,196–199 (2004).
  MedlineGoogle Scholar
• 136  Ross W, Petrovitch H, Abbott RD, Tanner CM, Popper P, Masaki K: Association of olfactory dysfunction with risk of future Parkinson's disease. Mov. Disord.20(10),P439 (2005) (Abstract).
  Google Scholar